FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | | 庫存股份變動 | 每股發行/出售價 (註4) ...

Group 1 - CRO concept stocks have shown significant gains, with notable increases in share prices for companies such as Viatris (up 12.83% to HKD 2.11), Zhaoyan New Drug (up 9.23% to HKD 24.62), and others [1] - WuXi AppTec has raised its full-year sales forecast after reporting a 141.6% year-on-year increase in TIDES business revenue, reaching RMB 5.03 billion in the first half of the year, driven by high demand in the GLP-1 sector [1] - CICC believes that the valuation center for innovative drug sectors has been adjusted upwards, which will enhance domestic new drug R&D demand and increase financing activity for primary innovative drug projects [1] Group 2 - The U.S. Bureau of Labor Statistics reported stable inflation in July, reducing barriers for potential interest rate cuts by the Federal Reserve in September, indicating a recovery trend in overall investment and financing [2] - The domestic market for preclinical CRO, clinical CRO, and CDMO services has stabilized in pricing, with a steady recovery in new orders expected to lead to an industry turnaround [2] - Internationally, the CDMO pricing system remains reasonable, and the impact of high pandemic baselines has been absorbed, suggesting a positive trend for overseas orders [2]

Group 1 - CRO concept stocks have shown significant gains, with notable increases in share prices for companies such as Viatris Bio (+12.83%), Zhaoyan New Drug (+9.23%), and others [1] - WuXi AppTec has raised its full-year sales forecast after reporting a 141.6% year-on-year increase in TIDES business revenue, reaching RMB 5.03 billion in the first half of the year, driven by high demand in the GLP-1 sector [1] - CICC believes that the valuation center for innovative drug sectors has been adjusted upwards, which will enhance domestic new drug R&D demand and increase financing activity for primary innovative drug projects [1] Group 2 - The U.S. Bureau of Labor Statistics reported stable inflation in July, reducing barriers for potential interest rate cuts by the Federal Reserve in September [2] - Overall investment and financing trends are showing signs of recovery, with prices for preclinical CRO, clinical CRO, and CDMO services stabilizing [2] - The international CDMO business maintains a reasonable pricing structure, with the impact of high pandemic baselines now absorbed [2]

Group 1 - The Hong Kong stock market showed strong performance on August 13, with the Hang Seng Index rising by 1.88% and the Hang Seng Tech Index increasing by 2.35%, particularly driven by the healthcare sector [1] - The Hong Kong Innovative Drug 50 ETF (513780) closed up by 3.38% with a turnover rate exceeding 18% and a transaction volume of over 400 million yuan, indicating strong investor interest [1] - Notably, the Hong Kong Innovative Drug 50 ETF (513780) experienced a net inflow of 1.07 billion yuan over the past 15 trading days, and it has gained over 92% year-to-date as of August 12 [1] Group 2 - The National Healthcare Security Administration announced the preliminary review results for the 2025 medical insurance directory and commercial insurance innovative drug directory, with 534 drugs passing the basic medical insurance directory review and 121 drugs passing the commercial insurance innovative drug directory review [2] - High-priced innovative drugs, including CAR-T therapies, are seeking inclusion in the commercial insurance innovative drug directory, indicating a push for diversified payment methods for innovative drugs [2] - Analysts suggest that the rise of innovative drugs is sustainable, recommending attention to companies with rich pipeline layouts, high-potential single innovative drugs, and leading technology platforms in the sector [2]

证券时报记者 陈澄 数据显示，截至2024年末，药明康德整体活跃客户约6000家。其中，持续经营业务截至年末活跃客户约 5500家，持续经营业务全年新增客户约1000家，全球各地客户对公司服务的需求持续增长。截至2024年 末，公司持续经营业务在手订单493.1亿元，同比增长47.0%。 7月10日晚间，药明康德（603259）发布2025年半年度业绩预告，预计上半年实现营收约207.99亿元， 同比增长约20.64%；预计实现归属于股东净利润约85.61亿元，同比增长约101.92%。 分析人士认为，药明康德业绩与全球制药行业发展以及新药研发投入密切相关，在全球制药行业蓬勃发 展的推动下，公司的主营业务有着广阔的发展空间，伴随着全球各国经济的发展、全球人口总量的增 长、人口老龄化程度的提高、科技进步、医疗开支上升以及大众对于健康生活的需求不断增强，预计全 球制药市场规模以及对于医药研发服务的需求仍然将持续增长。 药明康德在半年度业绩预告中表示，公司持续聚焦独特的"一体化、端到端"CRDMO（合同研究、开发 与生产）业务模式，紧抓客户对赋能需求的确定性，不断拓展新能力、建设新产能，持续优化生产工艺 和提高经营 ...

Core Insights - WuXi AppTec (603259) reported a strong performance in the first half of 2025, with revenue reaching 20.799 billion yuan, a year-on-year increase of 20.64%, and net profit attributable to shareholders rising by 101.92% to 8.56 billion yuan [1][2] Group 1: Financial Performance - The company achieved a revenue of 20.41 billion yuan from continuing operations, with a year-on-year growth of 24.24% [1] - The TIDES business (oligonucleotides and peptides) saw significant growth, with revenue reaching 5.03 billion yuan, a year-on-year increase of 141.6% [2] - The company completed cash dividends totaling 3.84 billion yuan in the first half of 2025, including 2.83 billion yuan for the 2024 fiscal year and a special dividend of 1.01 billion yuan for 2025 [2] Group 2: Business Operations and Growth - The company reported a backlog of orders for continuing operations amounting to 56.69 billion yuan, a year-on-year increase of 37.2% [1] - Revenue from U.S. clients was 14.03 billion yuan, reflecting a year-on-year growth of 38.4%, while European clients contributed 2.33 billion yuan, growing by 9.2% [1] - The company is expanding its global footprint, with successful FDA inspections at its Changzhou and Taixing API bases and ongoing construction of its Middleton facility in the U.S. expected to be operational by the end of 2026 [3] Group 3: Future Outlook - The company raised its full-year revenue guidance, expecting a growth rate for continuing operations to be adjusted from 10%-15% to 13%-17% [3] - Overall revenue guidance was increased from 41.5 billion yuan - 43 billion yuan to 42.5 billion yuan - 43.5 billion yuan [3] - The CEO highlighted the unique advantages of the CRDMO business model and the commitment of the global team as key factors driving the company's strong growth momentum [3]

Group 1: Market Mechanisms and Trends - The regular delisting mechanism in China's capital market is showing effectiveness, with 30 companies announced for delisting this year, indicating a healthy market ecology is forming [1] - The A-share market has seen a significant increase in financing balance, surpassing 2 trillion yuan for the first time since July 2015, reflecting a more mature participant structure and improved regulatory system [5] Group 2: Fund Performance and Investment Strategies - Consumer-themed funds have shown a stark performance divergence, with some funds underperforming due to heavy investments in traditional consumer stocks, while others have excelled by capturing new trends, with returns exceeding 60% [2] - 99% of equity funds have reported positive returns over the past year, with an average return of 34.06%, highlighting the emergence of structural opportunities in the market [7] Group 3: Capital Inflows and Market Dynamics - Southbound capital has seen a net inflow of over 910 billion HKD this year, marking a historical high and contributing to a significant rise in the Hong Kong stock market, with the Hang Seng Index up over 24% [3] - The Hong Kong refinancing market has experienced explosive growth, with over 240 companies raising 183.9 billion HKD, primarily driven by new economy sectors [8] Group 4: Policy and Economic Support - Various measures are being implemented to enhance investment and stimulate private sector activity, with new business registrations increasing by 4.6% for private enterprises in the first half of the year [4] - A new fiscal subsidy policy for personal consumption loans has been introduced, aimed at supporting consumer spending in key areas such as education and healthcare [11] Group 5: IPO Trends - The Hong Kong market is becoming a popular destination for AI companies seeking IPOs, with 213 companies having submitted applications, including around 50 AI firms [13]

Core Insights - The Hong Kong stock refinancing market is experiencing unprecedented prosperity, with over 240 companies completing refinancing totaling HKD 183.9 billion as of August 6, 2023, which is 2.17 times the total refinancing amount for the entire year of 2024, indicating strong market vitality [1] - New economy enterprises are the main players in this financing wave, with leading companies like BYD, Xiaomi Group, and WuXi AppTec leading the fundraising efforts [1][2] Group 1: Financing Details - BYD leads the pack with a placement amount of HKD 43.38 billion, followed closely by Xiaomi Group at HKD 42.6 billion, and WuXi AppTec at HKD 7.647 billion, together accounting for approximately 50% of the total placement amount in Hong Kong this year [2][3] - Other notable companies such as Horizon Robotics, ZhongAn Online, and China RuYi have raised over HKD 3 billion, while hard-tech firms like SenseTime and UBTECH also performed well [2] Group 2: Institutional Investor Participation - The participation of international institutional investors is a significant phenomenon in the Hong Kong refinancing market, with notable long-term fund Wujie Capital frequently making moves, including a planned investment of HKD 1.308 billion in Fourth Paradigm and HKD 2.5 billion in SenseTime [3][4] - Wujie Capital aims to establish a long-term presence in the Middle East, having obtained a financial license in Abu Dhabi, and is actively investing in new economy enterprises [3] Group 3: Strategic Partnerships and Value - The involvement of institutional investors brings strategic value beyond mere capital injection, enhancing market confidence in the companies' prospects and attracting more attention [5] - Institutional investors can help companies improve governance structures, increase transparency, and leverage their resources for business development, which is crucial for Chinese enterprises in the new economy sector as they expand globally [5] - BYD has announced a strategic partnership with Al-Futtaim Group to deepen collaboration in the electric vehicle sector, exploring growth opportunities based on regional cooperation [5][6] Group 4: Long-term Funding and R&D - The increased participation of long-term capital is expected to provide stable expectations for technology research and development in new economy enterprises [6] - Wujie Capital's collaboration with SenseTime and its spin-off Sunrise aims to explore strategic synergies in building a computing foundation for embodied intelligence and digital finance, promoting the globalization of AI chips and the construction of an AI capital ecosystem [6]

Core Insights - The Hong Kong stock market has experienced explosive growth in the refinancing sector this year, with over 240 companies raising a total of HKD 183.9 billion, which is 2.17 times the total refinancing amount for the entire year of 2024 [1][2] - New economy companies, such as BYD, Xiaomi, and WuXi AppTec, are leading the charge in equity financing, accounting for approximately 50% of the total amount raised this year [2][3] - Institutional investors, including sovereign funds and long-term funds, have played a significant role in this refinancing wave, indicating strong market confidence in quality enterprises [1][2] Company Highlights - WuXi AppTec completed a placement of 73.8 million H-shares, raising HKD 7.647 billion, with 90% of the funds allocated for global business expansion and capacity building [1] - BYD led the equity financing with HKD 43.383 billion, attracting numerous top-tier long-term investors and sovereign funds, including a strategic investment of HKD 3.5 billion from the Al-Futtaim family office [3][5] - The participation of well-known long-term funds, such as Wujing Capital, has been notable, with significant investments in companies like Fourth Paradigm and SenseTime [2][5] Strategic Implications - The involvement of institutional investors not only provides capital but also brings strategic value, enhancing market confidence and improving corporate governance [4] - Collaborations with institutional investors can help companies navigate local markets and establish partnerships, particularly in the new economy sector [4][5] - BYD's partnership with Al-Futtaim aims to deepen collaboration in the electric vehicle sector, supporting its international expansion strategy [5] Market Dynamics - The influx of institutional capital is expected to stabilize stock prices and improve shareholder structures, which can enhance investor confidence [3][4] - However, the large-scale refinancing has raised concerns about equity dilution among existing shareholders, which could impact investor sentiment [6][7] - Companies are exploring various strategies to mitigate dilution effects, such as optimizing financing structures and demonstrating efficient use of funds [6][7]

表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 1). | 購回股份(或其他證券)但沒有註銷 | 302,500 | 0.01 % | RMB | 66.14 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年6月26日，本公司實施2025年以集中競價交易方式回購本公司 | | | | | | | A股股份方案（"2025年第一次回購"），并回購302,500股A股股份。 | | | | | | | 變動日期 2025年6月26日 | | | | | | 2). | 購回股份(或其他證券)但沒有註銷 | 303,367 | | | | | | | | 0.01 % | RMB | 65.96 | | | 茲提述本公司於2025年3月17日 ...